BioStem Technologies, Inc.
BSEMAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Aug 24, 2026 | H.C. Wainwright | Swayampakula Ramakanth | $7.00(+98%) | $3.54 | StreetInsider |
| May 6, 2026 | H.C. Wainwright | Swayampakula Ramakanth | $9.00(+114%) | $4.21 | TheFly |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.43| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 12, 2026 | $-0.52 | $-0.50 | $7.9M | $6.4M |
| May 14, 2026 | $-0.52 | $-0.28 | $6.1M | $5.7M |
| Mar 24, 2026 | $-0.67 | $0.02 | $10.1M | $55.2M |
| Nov 13, 2025 | $0.03 | $0.02 | $10.5M | $55.2M |
| Aug 14, 2025 | $-0.03 | $0.32 | $49.3M | $78.2M |
| May 12, 2025 | $0.17 | $1.25 | $72.5M | $101.1M |
| Apr 14, 2025 | $0.94 | $0.37 | $102.9M | $86.7M |
| Nov 12, 2024 | $0.32 | $0.36 | $82.6M | $86.7M |
News
POMPANO BEACH, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announces it will release its third quarter 2026 financial results on Thursday, November 12, 2026, and will host a conference call and webcast at 4:30 PM ET.
Leadership investment supports expanded hospital commercial push PR Audio: POMPANO BEACH, Fla., October 8, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
POMPANO BEACH, Fla., Oct. 08, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced its Chair and Chief Executive Officer, Jason Matuszewski, and Chief Operating Officer, Andrew Van Vurst, each exercised a portion of their outstanding options to purchase 250,000 shares of BioStem common stock at…
Century Therapeutics (NASDAQ: IPSC - Get Free Report) and BioStem Technologies (OTCMKTS:BSEM - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings. Analyst Ratings This is a breakdown of
Newly issued U.S. Patent and pending allowances in the U.S. and Mexico extend protection for the company's sterile placental allograft, micronized wound care, and umbilical cord extract technologies PR Audio: POMPANO BEACH, Fla., October 1, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
POMPANO BEACH, Fla., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that the United States Patent and Trademark Office (USPTO) has issued one patent and three notices of allowance for additional patent applications and the Mexican Institute of Industrial Property (IMPI) has issue…
POMPANO BEACH, Fla., September 30, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc.
POMPANO BEACH, Fla., Sept. 30, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that it has entered into definitive agreements for the issuance and sale of 735,296 shares of the Company's common stock, Series A warrants to purchase up to an aggregate of 735,296 shares of common stock and Ser…
West Palm Beach, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform.
PR Audio: PR Video Overview: POMPANO BEACH, Fla., September 18, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies, Inc.
POMPANO BEACH, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a $40 million Committed Equity Facility (the “CEF”) with Roth Principal Investments, LLC (“Roth”), an affiliate of CR Financial Holdings, Inc., the holding company for Roth Capital Partners.
Additions extend BioStem's hospital channel to its BioRetain® wound care line PR Audio: POMPANO BEACH, Fla., September 4, 2026 – PRISM MediaWire (Press Release Service – Press Release Distribution) – BioStem Technologies Inc.
POMPANO BEACH, Fla., Sept. 04, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that VENDAJE® and VENDAJE AC® have been added to the Company's existing contracts with Vizient, Inc. and Premier, Inc., two of the nation's largest Group Purchasing Organizations (GPOs).
POMPANO BEACH, Fla., Sept. 03, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the H.C.
BioStem Technologies OTCMKTS: BSEM outlined its strategy to expand in surgical applications, shift its revenue mix away from physician-office wound care and bring manufacturing of acquired products into its Florida facility.
BioStem Technologies (OTCMKTS:BSEM - Get Free Report) and Enlivex Therapeutics (NASDAQ: ENLV - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, analyst recommendations, profitability, dividends and valuation. Insider and Institutional Ownership 1.0% of Enlivex
POMPANO BEACH, Fla., Aug. 14, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (Nasdaq: BSEM) (“BioStem” or the “Company”), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced that Company management will present at the Sidoti MicroCap Virtual Conference.
BioStem Technologies OTCMKTS: BSEM reported second-quarter revenue of $7.9 million as the company continued its transition to a predominantly hospital-focused commercial model. Revenue increased from $6.1 million in the first quarter, supported by higher hospital sales, expanded commercial coverage and a full quarter of contribution from its acquired business.
BioStem Technologies, Inc. (BSEM) Q2 2026 Earnings Call Transcript
BioStem Technologies, Inc. (BSEM) came out with a quarterly loss of $0.52 per share versus the Zacks Consensus Estimate of a loss of $0.5. This compares to earnings of $0.11 per share a year ago.